History, dynamics, and public health importance of malaria parasite resistance.
about
Estimating the global clinical burden of Plasmodium falciparum malaria in 2007Parasitostatic effect of maslinic acid. I. Growth arrest of Plasmodium falciparum intraerythrocytic stagesA new method for detection of pfmdr1 mutations in Plasmodium falciparum DNA using real-time PCRWolbachia Endobacteria in Natural Populations of Culex pipiens of Iran and Its Phylogenetic CongruenceMitigating the threat of artemisinin resistance in Africa: improvement of drug-resistance surveillance and response systemsImaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug DiscoveryImpact of home-based management of malaria on health outcomes in Africa: a systematic review of the evidenceChloroquine clinical failures in P. falciparum malaria are associated with mutant Pfmdr-1, not Pfcrt in MadagascarIdentification of a small molecule that modifies MglA/SspA interaction and impairs intramacrophage survival of Francisella tularensisAggressive chemotherapy and the selection of drug resistant pathogensChloroquine-resistant isoforms of the Plasmodium falciparum chloroquine resistance transporter acidify lysosomal pH in HEK293 cells more than chloroquine-sensitive isoforms.Antimalarial drug use in general populations of tropical Africa.Benefits of using multiple first-line therapies against malaria.Infection of the malaria mosquito, Anopheles gambiae, with two species of entomopathogenic fungi: effects of concentration, co-formulation, exposure time and persistenceMapping the origins and spread of antifolate-resistant malaria parasites.Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.A malaria outbreak in Naxalbari, Darjeeling district, West Bengal, India, 2005: weaknesses in disease control, important risk factors.Screening of traditionally used plants for in vivo antimalarial activity in mice.In vivo antiplasmodial activity evaluation of the leaves of Balanites rotundifolia (Van Tiegh.) Blatter (Balanitaceae) against Plasmodium berghei.Molecular surveillance of Plasmodium falciparum resistance to artemisinin-based combination therapies in the Democratic Republic of Congo.Independent origin of plasmodium falciparum antifolate super-resistance, Uganda, Tanzania, and Ethiopia.Plasmodium falciparum isolates from Angola show the StctVMNT haplotype in the pfcrt gene.Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study.Identification of pyrimethamine- and chloroquine-resistant Plasmodium falciparum in Africa between 1984 and 1998: genotyping of archive blood samplesAnti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations.Monitoring of malaria parasite resistance to chloroquine and sulphadoxine-pyrimethamine in the Solomon Islands by DNA microarray technologyTarget assessment for antiparasitic drug discovery.Five-year tracking of Plasmodium falciparum allele frequencies in a holoendemic area with indistinct seasonal transitions.The outcome of a test-treat package versus routine outpatient care for Ghanaian children with fever: a pragmatic randomized control trialEffectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective studyAntimalarial drug resistance of Plasmodium falciparum in India: changes over time and spaceTherapeutic efficacy of sulphadoxine-pyrimethamine and chloroquine for the treatment of uncomplicated malaria in pregnancy in Burkina Faso.Defining the relationship between Plasmodium falciparum parasite rate and clinical disease: statistical models for disease burden estimation.The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapyPerformance of Paracheck™-Pf, SD Bioline malaria Ag-Pf and SD Bioline malaria Ag-Pf/pan for diagnosis of falciparum malaria in the Central African Republic.Methodological issues in the assessment of antimalarial drug treatment: analysis of 13 studies in eight African countries from 2001 to 2004.Exposure to anti-malarial drugs and monitoring of adverse drug reactions using toll-free mobile phone calls in private retail sector in Sagamu, Nigeria: implications for pharmacovigilanceImpact of treatment heterogeneity on drug resistance and supply chain costsMolecular markers of antifolate resistance in Plasmodium falciparum isolates from Luanda, Angola.Malaria in the post-genomics era: light at the end of the tunnel or just another train?
P2860
Q17485684-A8BDE112-ABDF-4DEA-AD1E-E46F187D1020Q21034076-9EFA1783-25F3-4687-83C0-BC6728CD3CACQ24791458-C56B2CCB-780D-4F84-8442-B387DDDF70CEQ26315322-EED4F3FD-8A54-4704-AC30-882ECA5802CBQ27000750-EC163326-ABBD-499B-B14B-6CF3A6FB1E6EQ27861956-AFC60FDE-2B8E-4731-AFEB-8CA77B2AC338Q28222513-E1DDF7EC-2EAF-4BFB-899B-4D13E84747A4Q28475757-FFBCC2DE-8421-44B4-B263-1C8B43D4664EQ28485250-DDCA24FD-3BEF-4976-893F-E921BD9DD7FDQ28533328-31D86C87-CB3B-49DA-8C67-B4CCFDE10936Q30357176-9CB797F9-DD26-4D73-A8AB-B7B77150B831Q30482961-5DE37298-0489-4580-A2FC-CD9C93BFCB42Q30483653-56320CBE-EC4C-46D2-898E-AC398B119550Q30492832-81B295DF-E0CA-4B97-88BC-234302D0F41AQ33510240-296F3DA2-321A-44E1-B31B-657953B38669Q33516563-83D0B0A7-519A-4613-85DB-F1595A983F99Q33555954-F0A36FC1-54F4-496D-AAC3-A2FBF8FDFCE8Q33630564-0C1D2FEB-3DA3-4D54-9FED-C5B8C9297999Q33631286-84A613BA-36CE-4090-8278-1F16564528C5Q33778751-69604E61-881E-4F74-A5D8-FDF55E0CD913Q33950981-A66A7B31-4118-4B20-B745-86AE39C1698FQ33968854-C1189011-510A-457B-A4BE-73F988C2AB35Q34055721-29031319-5495-4176-B7E3-0D79AF17440CQ34114498-E16363B7-922E-4DD3-BB5A-A0695D7BCA48Q34134036-444FA552-097D-474D-B9BB-EF8DD080BAC2Q34221842-2D7C3739-BB39-44A5-AA11-F81D705B17ECQ34301994-5AE936C8-384A-4B50-83EC-7036A282565EQ34488950-0D418FB3-3F9E-4462-974C-016128616FBFQ34651041-6E25D216-2908-40D7-A999-87AE8AE74D4AQ34728230-2171A509-0FB2-451A-8D36-00C928B44912Q34743254-1A881C30-7DB4-45D4-BCD3-9920A1F519C0Q34944810-D607A223-FA45-4AC6-BA5F-059F296B046CQ34995744-71ADF046-5C99-44AA-A604-B01D98E16F49Q35092451-9CB48F46-B48D-49FB-8405-305C5534B60BQ35102716-0FD8BD8A-54F6-483E-88F2-7CD0B29A14AFQ35127949-A90168C7-053B-49F2-93AB-E698BFCF65C7Q35183422-D21B8053-1FA3-4DC8-AE4F-A667612A9BD2Q35221886-43BE6FD3-3FD9-4244-BD13-FC3059EC8252Q35221902-BFEAF14F-6BE2-486B-96B0-F5CF0831AB43Q35522550-A73D9AEF-D571-4C71-9C3E-D49DFC3DF7B6
P2860
History, dynamics, and public health importance of malaria parasite resistance.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
History, dynamics, and public health importance of malaria parasite resistance.
@ast
History, dynamics, and public health importance of malaria parasite resistance.
@en
type
label
History, dynamics, and public health importance of malaria parasite resistance.
@ast
History, dynamics, and public health importance of malaria parasite resistance.
@en
prefLabel
History, dynamics, and public health importance of malaria parasite resistance.
@ast
History, dynamics, and public health importance of malaria parasite resistance.
@en
P2860
P1476
History, dynamics, and public health importance of malaria parasite resistance.
@en
P2093
Ambrose O Talisuna
Peter Bloland
P2860
P304
P356
10.1128/CMR.17.1.235-254.2004
P407
P577
2004-01-01T00:00:00Z